Acasti Pharma Stock Buy Hold or Sell Recommendation
| ACST Stock | USD 2.90 0.02 0.69% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Acasti Pharma is 'Strong Hold'. Macroaxis provides Acasti Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ACST positions. The advice algorithm takes into account all of Acasti Pharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Acasti Pharma's buy or sell advice are summarized below:
Real Value 2.88 | Target Price 1.96 | Hype Value 2.88 | Market Value 2.9 | Naive Value 2.42 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Acasti Pharma given historical horizon and risk tolerance towards Acasti Pharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Acasti Pharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Acasti |
Execute Acasti Pharma Buy or Sell Advice
The Acasti recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Acasti Pharma. Macroaxis does not own or have any residual interests in Acasti Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Acasti Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | OK | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Acasti Pharma Trading Alerts and Improvement Suggestions
| Acasti Pharma had very high historical volatility over the last 90 days | |
| Net Loss for the year was (42.43 M) with profit before overhead, payroll, taxes, and interest of 120 K. | |
| Acasti Pharma currently holds about 38.39 M in cash with (15.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Acasti Pharma Stock Passes Above Two Hundred Day Moving Average of 2.65 - Defense World |
Acasti Pharma Returns Distribution Density
The distribution of Acasti Pharma's historical returns is an attempt to chart the uncertainty of Acasti Pharma's future price movements. The chart of the probability distribution of Acasti Pharma daily returns describes the distribution of returns around its average expected value. We use Acasti Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Acasti Pharma returns is essential to provide solid investment advice for Acasti Pharma.
| Mean Return | 0.31 | Value At Risk | -4.78 | Potential Upside | 7.40 | Standard Deviation | 3.52 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Acasti Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Acasti Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Acasti Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acasti Pharma backward and forwards among themselves. Acasti Pharma's institutional investor refers to the entity that pools money to purchase Acasti Pharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2023-12-31 | 494.7 K | Two Sigma Securities, Llc | 2023-09-30 | 0.0 | Adar1 Capital Management Llc | 2023-12-31 | 34.5 K | Royal Bank Of Canada | 2023-12-31 | 31.6 K | Ubs Group Ag | 2023-12-31 | 5.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.9 K | Advisory Services Network, Llc | 2023-12-31 | 41.0 | Ica Group Wealth Management, Llc | 2023-12-31 | 9.0 | Nbc Securities Inc | 2023-09-30 | 2.0 | Td Waterhouse Canada Inc | 2023-12-31 | 0.0 | Jpmorgan Chase & Co | 2023-12-31 | 0.0 |
Acasti Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.6M) | 36.7M | (20.6M) | (2.5M) | (2.8M) | (2.7M) | |
| Free Cash Flow | (23.3M) | (14.4M) | (17.2M) | (15.9M) | (14.3M) | (15.1M) | |
| Depreciation | 2.3M | 924K | 1K | 124K | 142.6K | 135.5K | |
| Other Non Cash Items | 145K | 264K | (5.3M) | 33.9M | 39.0M | 41.0M | |
| Capital Expenditures | 319K | 69K | 0.0 | 17K | 19.6K | 18.6K | |
| Net Income | (25.5M) | (19.7M) | (9.8M) | (42.4M) | (38.2M) | (36.3M) | |
| End Period Cash Flow | 14.2M | 50.9M | 30.3M | 27.9M | 32.1M | 33.7M | |
| Investments | 8.1M | (9.8M) | (3.5M) | 13.2M | 15.1M | 15.9M | |
| Change To Netincome | 6.1M | 3.5M | 10.1M | (4.6M) | (5.3M) | (5.1M) |
Acasti Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Acasti Pharma or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Acasti Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Acasti stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.15 | |
β | Beta against NYSE Composite | 1.77 | |
σ | Overall volatility | 3.55 | |
Ir | Information ratio | 0.06 |
Acasti Pharma Volatility Alert
Acasti Pharma currently demonstrates below-average downside deviation. It has Information Ratio of 0.06 and Jensen Alpha of 0.15. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Acasti Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Acasti Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Acasti Pharma Fundamentals Vs Peers
Comparing Acasti Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Acasti Pharma's direct or indirect competition across all of the common fundamentals between Acasti Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Acasti Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Acasti Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Acasti Pharma to competition |
| Fundamentals | Acasti Pharma | Peer Average |
| Return On Equity | -0.48 | -0.31 |
| Return On Asset | -0.0792 | -0.14 |
| Current Valuation | 1.98 M | 16.62 B |
| Shares Outstanding | 9.4 M | 571.82 M |
| Shares Owned By Insiders | 16.02 % | 10.09 % |
| Shares Owned By Institutions | 12.13 % | 39.21 % |
| Number Of Shares Shorted | 1.41 K | 4.71 M |
| Price To Earning | 15.34 X | 28.72 X |
| Price To Book | 0.49 X | 9.51 X |
| Price To Sales | 208.39 X | 11.42 X |
| Gross Profit | 120 K | 27.38 B |
| EBITDA | 15.85 M | 3.9 B |
| Net Income | (42.43 M) | 570.98 M |
| Cash And Equivalents | 38.39 M | 2.7 B |
| Cash Per Share | 0.86 X | 5.01 X |
| Total Debt | 485 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 11.13 X | 2.16 X |
| Book Value Per Share | 6.88 X | 1.93 K |
| Cash Flow From Operations | (15.91 M) | 971.22 M |
| Short Ratio | 0.04 X | 4.00 X |
| Earnings Per Share | (5.68) X | 3.12 X |
| Target Price | 6.01 | |
| Beta | 1.53 | -0.15 |
| Market Capitalization | 27.07 M | 19.03 B |
| Total Asset | 79.12 M | 29.47 B |
| Retained Earnings | (198.27 M) | 9.33 B |
| Working Capital | 25.88 M | 1.48 B |
| Current Asset | 11.33 M | 9.34 B |
| Current Liabilities | 1.14 M | 7.9 B |
| Net Asset | 79.12 M |
Note: Acasti Pharma exotic insider transaction detected [view details]
Acasti Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Acasti . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 773.09 | |||
| Daily Balance Of Power | 0.069 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 3.02 | |||
| Day Typical Price | 2.98 | |||
| Price Action Indicator | (0.11) | |||
| Period Momentum Indicator | 0.02 |
About Acasti Pharma Buy or Sell Advice
When is the right time to buy or sell Acasti Pharma? Buying financial instruments such as Acasti Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 1.5M | 3.3M | 3.8M | 2.7M | Total Assets | 128.6M | 79.1M | 91.0M | 95.5M |
Use Investing Ideas to Build Portfolios
In addition to having Acasti Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Climate Change Thematic Idea Now
Climate Change
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Acasti Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Acasti Stock analysis
When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.68) | Revenue Per Share 0.005 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.